The US District Court for the Southern District of New York Imposes Lifetime Ban Against Pharmaceutical Executive and Requires $65 Million Payment for Antitrust Violation (Martin Shkreli)

e-Competitions (No. 105456, Mar. 2022)

7 Pages Posted: 15 Apr 2022

Date Written: March 7, 2022

Abstract

This short article discusses the ruling that imposed a lifetime ban on “Pharma Bro” Martin Shkreli, perhaps the most notorious “bad actor” in the pharmaceutical industry, and required that he pay $65 million in excess profits he obtained from anticompetitive conduct relating to the drug Daraprim.

The piece explains how the court found that Shkreli’s company, Vyera, had market power and how it employed two strategies to engage in an unreasonable restraint of trade. First, it used a closed distribution system, bottle limits, and a surveillance system to make it difficult for generics to obtain the samples needed for equivalence testing. And second, it used exclusive supply agreements that blocked access to the active pharmaceutical ingredient used in the drug.

It concludes that FTC v. Shkreli is an important case because of (1) its reminder of brand firms’ use of a vast array of activity to delay generic competition, (2) the sheer brashness of Shkreli’s belt-and-suspenders-and-braces approach, and (3) his lifetime ban from the pharmaceutical industry.

Keywords: pharmaceuticals, drugs, antitrust, Pharma Bro, Martin Shkreli

JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38

Suggested Citation

Carrier, Michael A., The US District Court for the Southern District of New York Imposes Lifetime Ban Against Pharmaceutical Executive and Requires $65 Million Payment for Antitrust Violation (Martin Shkreli) (March 7, 2022). e-Competitions (No. 105456, Mar. 2022), Available at SSRN: https://ssrn.com/abstract=4083903

Michael A. Carrier (Contact Author)

Rutgers Law School ( email )

217 North Fifth Street
Camden, NJ 08102-1203
United States
856-225-6380 (Phone)
856-225-6516 (Fax)

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
100
Abstract Views
493
Rank
484,015
PlumX Metrics